As an emerging method for detecting unique signals from the molecules of interest, magnetic resonance spectroscopy (MRS)[7] identifies IDH1 mutation by tracking D‐2‐hydroxyglutarate (D‐2HG), an oncometabolite of IDH1‐MUT glioma cells. The gene discussed is IDH1; the disease is central nervous system cancer.